Non-invasive fibrosis tests in Wilson Disease: Insights from the international Wilson Disease Registry and Barcelona Cohort.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), "A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases," 2023 (Hepatology 77(4):1428-1455)
… Fulminant Wilson (acute liver failure with Coombs-negative hemolysis, AST/ALT >2, low ALP, low uric acid) or decompensated cirrhosis warrants emergency transfer for liver transplant evaluation. …
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standard
Confirm the diagnosis with the Leipzig score integrating Kayser-Fleischer rings, ceruloplasmin, 24-hour urinary copper, hepatic copper, and ATP7B testing, then treat with lifelong therapy: symptomatic patients begin decoppering with a chelator, either D-penicillamine or trientine, and transition to maintenance once decoppering is achieved, while asymptomatic or presymptomatic patients may begin with a lower-dose chelator or zinc; maintenance may be a lower-dose chelator (D-penicillamine or trientine) or full-dose zinc. Fulminant Wilson (acute liver failure with Coombs-negative hemolysis, AST/ALT >2, low ALP, low uric acid) or decompensated cirrhosis warrants emergency transfer for liver transplant evaluation. Screen all first-degree relatives.